Figure 6.
Novel therapies targeting the interaction between OX40 and OX40L include monoclonal antibodies against OX40 (rocatinlimab and telazorlimab) and OX40L (amlitelimab).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.